CNS Drugs

Acknowledgement
pp. 1053-1055(3)
Author: Adis International Limited

Interferons in Relapsing-Remitting Multiple Sclerosis: Are There Benefits from Long-Term Use?
pp. 1057-1070(14)
Authors: Oscar Fernández

Nitrone-Related Therapeutics: Potential of NXY-059 for the Treatment of Acute Ischaemic Stroke
pp. 1071-1084(14)
Authors: Kirk R. Maples; A. Richard Green; Robert A. Floyd

Remifentanil Update: Clinical Science and Utility
pp. 1085-1104(20)
Authors: Richard Beers; Enrico Camporesi

Role of the Serotonergic System in the Neurobiology of Alcoholism: Implications for Treatment
pp. 1105-1118(14)
Author: Bankole A. Johnson

Antidepressant Treatment and Risk of Suicide Attempt by Adolescents with Major Depressive Disorder: A Propensity-Adjusted Retrospective Cohort Study
pp. 1119-1132(14)
Authors: Robert J. Valuck; Anne M. Libby; Marion R. Sills; Alexis A. Giese; Richard R. Allen

Acute Treatment of Migraine with Zolmitriptan 5mg Orally Disintegrating Tablet
pp. 1133-1141(9)
Authors: Egilius L.H. Spierings; Alan M. Rapoport; David W. Dodick; Bruce Charlesworth

Impact of Rivastigmine Use on the Risk of Nursing Home Placement in a US Sample
pp. 1143-1148(6)
Authors: Kathleen M. Beusterien; Simu K. Thomas; Douglas Gause; Miriam Kimel; Stephen Arcona; Dario Mirski

The PROMISE Study: PROphylaxis of MIgraine with SEglor^® (Dihydroergotamine Mesilate) in French Primary Care
pp. 1149-1163(15)
Authors: André Pradalier; Michel Lantéri-Minet; Gilles Géraud; Hervé Allain; Christian Lucas; Antonio Delgado

Zotepine for Behavioural and Psychological Symptoms in Dementia: An Open-Label Study
pp. 1165-1165(1)
Authors: Michael K. Rainer; Christine Krüger-Rainer; Manfred Haushofer; Hermann AM Mucke